Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Intravascular Imaging for Guiding Stent Implantation Ensures Safer Stenting Procedures

By HospiMedica International staff writers
Posted on 16 Apr 2025

Patients diagnosed with coronary artery disease, which is caused by plaque accumulation within the arteries leading to chest pain, shortness of breath, and potential heart attacks, frequently undergo percutaneous coronary intervention (PCI). More...

This non-surgical procedure involves the insertion of a catheter by interventional cardiologists to place stents in blocked coronary arteries, thereby restoring blood flow. Approximately one-third of these cases in the United States, which amounts to hundreds of thousands annually, involve moderate to severe calcified lesions, where calcium accumulates within the arteries. Around 10% of these cases are categorized as severe, where the arteries essentially turn to bone, making the stenting procedure more complex and risky. Typically, interventional cardiologists use angiography to guide the PCI catheter, which involves injecting a special dye and using X-rays to visualize blood flow through the heart arteries, helping to highlight blockages.

However, angiography has inherent limitations, such as its inability to accurately assess the true size of the arteries and the composition of the plaque, and its shortcomings in determining whether the stent is fully expanded after PCI. Angiography also struggles to identify other complications that might affect the safety and effectiveness of the procedure. These challenges are amplified when dealing with calcified coronary arteries. New research now shows that using intravascular imaging (IVI) to guide stent implantation during complex stenting procedures provides a safer and more effective solution for patients with severely calcified coronary artery disease compared to traditional angiography. These findings come from the largest clinical trial of its kind, which compared the two methods during PCI.

The ECLIPSE study, funded by Abbott Vascular, Inc. (Santa Clara, CA, USA) and led by Mount Sinai Health System (New York, NY, USA), analyzed the outcomes of PCI in patients with severely calcified lesions, involving 2,005 participants. The goal was to assess whether IVI guidance could improve survival rates free from adverse cardiac events when compared to angiography. Patients with severely calcified coronary lesions were randomized at 104 sites across the U.S. One group of 1,246 patients, or 62%, underwent PCI with guidance from either optical coherence tomography (OCT) or intravascular ultrasound (IVUS), while 759 patients, or 38%, had PCI guided by angiography. The primary endpoint was the one-year rate of target vessel failure, which included cardiac death, target-vessel myocardial infarction, or ischemia-driven target-vessel revascularization.

The results showed that overall rates of target vessel failure were 26% lower in patients who received IVI guidance compared to those who underwent angiography guidance. Additionally, there was a significant reduction in all-cause death, stent thrombosis, and revascularization of target lesions and vessels among those treated with intravascular imaging compared to angiography. Further analysis of the two imaging modalities—IVUS and OCT—was conducted to determine which was more effective. The unadjusted analysis revealed that patients with OCT guidance had better outcomes than those with IVUS; however, when adjusting for factors such as age, diabetes, and the number and severity of lesions, the differences were not statistically significant.

OCT and IVUS provide detailed, high-resolution images of the coronary arteries and blockages, offering a more accurate and specific view than traditional coronary angiography. These imaging techniques also enable a better assessment of the adequacy of the implanted stent. Both imaging methods help in more accurately measuring the dimensions and composition of the vessel and plaque and in better assessing the quality of stent implantation. The findings from the ECLIPSE trial, presented at the American College of Cardiology Scientific Session (ACC.25), could lead to significant changes in treatment strategies for high-risk patients.

“The ECLIPSE trial shows that use of IVI to guide coronary stenting in severely calcified lesions prevents death, stent thrombosis, and unplanned repeat procedures in this high-risk patient population,” said first author Gregg W. Stone, MD. “These results extend the strong recommendations from recent U.S. and European societal guidelines that intravascular imaging with either optical coherence tomography (OCT) or intravascular ultrasound (IVUS) should be routinely used during complex coronary stent procedures.”


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.